Intellia Therapeutics Inc (OQ:NTLA)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 40 Erie St Ste 130
CAMBRIDGE MA 02139-4254
Tel: 1-857-7061612
Website: https://www.intelliatx.com
IR: See website
<
Key People
John M. Leonard
President, Chief Executive Officer, Director
Glenn G. Goddard
Chief Financial Officer, Executive Vice President, Treasurer
Eliana Clark
Executive Vice President, Chief Technology Officer
Laura Sepp-Lorenzino
Executive Vice President, Chief Scientific Officer
James Basta
Executive Vice President, General Counsel, Corporate Secretary
Derek Hicks
Executive Vice President, chief business officer
David Lebwohl
Executive Vice President, Chief Medical Officer
Michael P. Dube
Chief Accounting Officer, Vice President
 
Business Overview
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.
Financial Overview
For the fiscal year ended 31 December 2023, Intellia Therapeutics Inc revenues decreased 30% to $36.3M. Net loss increased 1% to $481.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects genome editing-based therapies segment loss increase of 12% to $515.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$6.16 to -$5.42.
Employees: 526 as of Feb 16, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $1,186M as of Dec 31, 2023
Annual revenue (TTM): $36.28M as of Dec 31, 2023
EBITDA (TTM): -$506.32M as of Dec 31, 2023
Net annual income (TTM): -$481.19M as of Dec 31, 2023
Free cash flow (TTM): -$408.07M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 96,106,405 as of Feb 16, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.